217 related articles for article (PubMed ID: 17562592)
41. Manifestations of fulminant CD8 T-cell post-transplant lymphoproliferative disorder following the administration of rituximab for lymphadenopathy with a high level of Epstein-Barr Virus (EBV) replication after allogeneic hematopoietic stem cell transplantation.
Tanaka T; Takizawa J; Miyakoshi S; Kozakai T; Fuse K; Shibasaki Y; Moriyama M; Ohshima K; Toba K; Furukawa T; Sone H; Masuko M
Intern Med; 2014; 53(18):2115-9. PubMed ID: 25224199
[TBL] [Abstract][Full Text] [Related]
42. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
Bonney DK; Htwe EE; Turner A; Kelsey A; Shabani A; Hughes S; Hughes I; Wynn RF
Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
[TBL] [Abstract][Full Text] [Related]
43. Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review.
Chen S; An L; Han J; Zheng X; Zhang X; Li G; Zhang Y; Cao W; Lv M; Yang D; Jiang E; Pang A; Feng S
Transpl Immunol; 2023 Oct; 80():101895. PubMed ID: 37414267
[TBL] [Abstract][Full Text] [Related]
44. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
[TBL] [Abstract][Full Text] [Related]
45. Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation.
Herman J; Vandenberghe P; van den Heuvel I; Van Cleemput J; Winnepenninckx V; Van Damme-Lombaerts R
J Heart Lung Transplant; 2002 Dec; 21(12):1304-9. PubMed ID: 12490276
[TBL] [Abstract][Full Text] [Related]
46. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.
Kasow KA; Leung W; Horwitz EM; Woodard P; Handgretinger R; Hale GA
Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900
[TBL] [Abstract][Full Text] [Related]
47. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease.
Savoldo B; Rooney CM; Quiros-Tejeira RE; Caldwell Y; Wagner HJ; Lee T; Finegold MJ; Dotti G; Heslop HE; Goss JA
Am J Transplant; 2005 Mar; 5(3):566-72. PubMed ID: 15707412
[TBL] [Abstract][Full Text] [Related]
48. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab.
Patriarca F; Medeot M; Isola M; Battista ML; Sperotto A; Pipan C; Toffoletti E; Dozzo M; Michelutti A; Gregoraci G; Geromin A; Cerno M; Savignano C; Rinaldi C; Barbone F; Fanin R
Transpl Infect Dis; 2013 Jun; 15(3):259-67. PubMed ID: 23405972
[TBL] [Abstract][Full Text] [Related]
49. Toxoplasmic Encephalitis Followed by Primary EBV-Associated Post-Transplant Lymphoproliferative Disorder of the Central Nervous System in a Patient Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Report.
Mayumi A; Yamashita T; Matsuda I; Hikosaka K; Fujino S; Norose K; Kato Y; Hirota S; Nakajima T; Ogawa H; Ikegame K
Transplant Proc; 2020 Nov; 52(9):2858-2860. PubMed ID: 32873410
[TBL] [Abstract][Full Text] [Related]
50. Epstein-Barr virus-related lymphoproliferative disease after allogeneic bone marrow transplantation for severe aplastic anemia complicated by the syndrome of inappropriate secretion of antidiuretic hormone.
Ostronoff M; Ostronoff F; Florêncio R; Maior AP; Sucupira A; Calixto R; Domingues MC; Tagliari C
Leuk Lymphoma; 2007 Jun; 48(6):1244-6. PubMed ID: 17577796
[No Abstract] [Full Text] [Related]
51. [Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation].
Liu QF; Fan ZP; Luo XD; Zhang Y; Sun J
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(44):3123-6. PubMed ID: 19159594
[TBL] [Abstract][Full Text] [Related]
52. [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation].
Aimoto M; Yamane T; Inoue A; Momose D; Moriguchi-Aimoto R; Wada-Inoue E; Okamoto S; Koh H; Nakane T; Takeoka Y; Akahori-Nakamae M; Nishiki-Kosaka S; Terada Y; Nakamae H; Koh KR; Nakao T; Ohsawa M; Hino M
Rinsho Ketsueki; 2010 Dec; 51(12):1775-80. PubMed ID: 21258188
[TBL] [Abstract][Full Text] [Related]
53. [Successful donor lymphocyte infusion for Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia].
Yago K; Itoh M; Shimada H
Rinsho Ketsueki; 2001 Nov; 42(11):1105-10. PubMed ID: 11808079
[TBL] [Abstract][Full Text] [Related]
54. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
Meyer SC; Medinger M; Halter JP; Baldomero H; Hirsch HH; Tzankov A; Dirnhofer S; Passweg JR; Tichelli A
Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
[TBL] [Abstract][Full Text] [Related]
55. Post-transplant lymphoproliferative disorder of the pediatric airway: Presentation and management.
O'Neill AF; Adil EA; Irace AL; Neff L; Davis IJ; Perez-Atayde AR; Voss SD; Weinberg O; Rahbar R
Int J Pediatr Otorhinolaryngol; 2016 Jul; 86():218-23. PubMed ID: 27260610
[TBL] [Abstract][Full Text] [Related]
56. Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges.
Kittan NA; Beier F; Kurz K; Niller HH; Egger L; Jilg W; Andreesen R; Holler E; Hildebrandt GC
Transpl Infect Dis; 2011 Oct; 13(5):524-30. PubMed ID: 21395956
[TBL] [Abstract][Full Text] [Related]
57. Rituximab for PTLD of the CNS: is it a 'no-brainer'?
Reshef R; Tsai DE
Onkologie; 2008 Dec; 31(12):650-1. PubMed ID: 19060501
[No Abstract] [Full Text] [Related]
58. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
59. Various initial presentations of Epstein-Barr virus infection-associated post-transplant lymphoproliferative disorder in pediatric liver transplantation recipients: Case series and literature review.
Simakachorn L; Tanpowpong P; Lertudomphonwanit C; Anurathapan U; Pakakasama S; Hongeng S; Treepongkaruna S; Phuapradit P
Pediatr Transplant; 2019 Mar; 23(2):e13357. PubMed ID: 30661283
[TBL] [Abstract][Full Text] [Related]
60. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
Muzaffar M; Taj A; Ratnam S
Am J Ther; 2010; 17(6):e230-3. PubMed ID: 19918163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
